COVID-19 Vaccine Choice May Matter for Older Adults, VA Data Suggest
A VA study found that Moderna's mRNA-1283 vaccine reduced COVID-19 risk by 35.9% and hospitalizations by 47% compared to Pfizer-BioNTech's BNT162b2 in veterans 65+. The study analyzed 294,000+ veterans, showing mRNA-1283's sustained durability and cardiovascular benefits. Researchers attributed the differences to mRNA-1283's targeted immune response. The findings may influence seasonal vaccine decisions for high-risk populations.
How this was made

The 30-second read
Why it matters
The study provides first‑time real‑world effectiveness data that could shift market expectations for both companies' COVID‑19 vaccine revenues and future contracts.
Market read
First‑report of comparative vaccine effectiveness may influence investor sentiment toward Moderna and Pfizer, affecting biotech sector dynamics.
What to watch
Supply chain constraints, pricing negotiations with governments, and upcoming FDA authorizations could moderate the impact of the efficacy gap.
Background
A VA study of over 294,000 veterans 65+ compares Moderna's mRNA-1283 and Pfizer's BNT162b2, finding significant reductions in COVID‑19 risk and hospitalizations for the Moderna vaccine.
Ticker impact
VA cohort study shows Moderna's mRNA-1283 cuts COVID-19 risk 35.9% versus Pfizer's BNT162b2.
likely upward pressure as market prices in superior efficacy.
First‑report of real‑world effectiveness gives Moderna a competitive edge, potentially increasing sales and contracts.
VA cohort study finds Pfizer's BNT162b2 less effective than Moderna's mRNA-1283 in older veterans.
likely downward pressure as investors reassess Pfizer's vaccine prospects.
First‑report of comparative effectiveness may dampen expectations for Pfizer's COVID‑19 vaccine sales.
Market effects
Boosts biotech/vaccine sector favoring Moderna, puts pressure on Pfizer and other COVID‑19 vaccine makers.
US market may react as VA data influences domestic vaccine procurement and investor sentiment.
New effectiveness data could affect global COVID‑19 vaccine demand and competitive dynamics.
Counterpoint
Pfizer may benefit if the data spurs additional booster campaigns or if regulatory bodies favor its broader safety record.
Key entities
- CompanyModerna Inc.
Developer of the mRNA-1283 COVID‑19 vaccine.
- CompanyPfizer Inc.
Manufacturer of the BNT162b2 (Comirnaty) COVID‑19 vaccine.
- Government AgencyU.S. Department of Veterans Affairs
Conducted the cohort study on vaccine effectiveness.




